Icon bought 6M shares of ENZN at mid $7s. Now ENZN is at mid $4s. ENZN distributed $2 special dividend and put itself on sell.
All of Forest's "new-nine" are on the table now. The next will be revenue and earnings. With existing generics, FRX faces fierce competitions, and there will be no clear view till 2016 except near-term revenue/earnings definitely going south. If Icon force it "on sell," the company is still worth some and has to sell with some discount.
Carl Ican is over the hill. He invests in loser companies, and then tries to bully them into giving him a special deal. The bloke should retire. FRX is going down for the fundamental reason that Lexapro is off patent and sales are down over 30% and profits are gone for the next few years. Carl should sell now and preserve his capital.